Oxa-azaspiro derivatives: a novel class of triple re-uptake inhibitors.
Bettati
Michela
M
Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline, Via Fleming 4, 37135 Verona, Italy.
Cavanni
Paolo
P
Di Fabio
Romano
R
Oliosi
Beatrice
B
Perini
Ornella
O
Scheid
Gunther
G
Tedesco
Giovanna
G
Zonzini
Laura
L
Micheli
Fabrizio
F
D001372:Aza Compounds / Q000737:chemistry / Q000494:pharmacology*; D002460:Cell Line; D050483:Dopamine Plasma Membrane Transport Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D015394:Molecular Structure; D050484:Norepinephrine Plasma Membrane Transport Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D050486:Serotonin Plasma Membrane Transport Proteins / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D013141:Spiro Compounds / Q000737:chemistry / Q000494:pharmacology*
D001372:Aza Compounds; D050483:Dopamine Plasma Membrane Transport Proteins; D050484:Norepinephrine Plasma Membrane Transport Proteins; D050486:Serotonin Plasma Membrane Transport Proteins; D017367:Selective Serotonin Reuptake Inhibitors; D013141:Spiro Compounds; C493227:SLC6A2 protein, human; C493230:SLC6A4 protein, human